Equities

Provexis PLC

Provexis PLC

Actions
Consumer Staples Food Producers
  • Price (GBX)0.525
  • Today's Change0.025 / 5.00%
  • Shares traded1.50m
  • 1 Year change-10.26%
  • Beta1.6708
Data delayed at least 20 minutes, as of Nov 06 2024 14:28 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Provexis plc is engaged in developing, licensing and selling the proprietary, scientifically proven Fruitflow heart-health functional food ingredient. Fruitflow is a natural extract from tomatoes, which has been shown in human trials to reduce the propensity for aberrant blood clotting, typically associated with cardiovascular disease, which can lead to heart attack and stroke. The extract is available in two formats, a syrup and a spray-dried powder and can be included in a range of food, beverage, and dietary supplement formats. Fruitflow is a highly concentrated form of bioactives that is lycopene-free and contains over 30 known anti-platelet compounds. The syrup and powder versions of Fruitflow are GRAS in the United States. The Company also offers Fruitflow+ Omega-3, a dietary supplement product. The Company sells its Fruitflow+ Omega-3 dietary supplement product direct to consumers and serves its Chinese cross-border e-commerce distributor for this product in China.

  • Revenue in GBP (TTM)801.96k
  • Net income in GBP-586.25k
  • Incorporated2004
  • Employees2.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Excellence SA-19.25bn-19.25bn8.62m82.00--1.68----------0.1691----------3.94--7.24--18.82--2.431.30--0.2611--14.5310.411,273.92--12.61--
Vinpai SA6.62m-2.88m9.13m44.00--4.62--1.38-1.13-1.132.790.702------179,558.40--------14.53---43.45--0.6061-4.370.6552--27.00---130.75------
Bio Planet SA51.01m110.11k9.64m--78.022.0114.370.18910.21410.214194.638.332.528.109.71--0.54313.180.87836.7228.6027.230.21591.170.47550.9120.00--26.3514.6662.6562.66-4.65--
Vanet Gida Sanayi Ic ve Dis Ticaret AS3.89m-621.36k10.14m2.00--2.52--2.61-1.11-1.116.977.190.9885--22.35---15.790.7737-18.390.78942.101.51-15.971.94--0.0360.000.00117.1698.01-233.61------
Flour Mills Kepenos SA48.74m695.43k10.78m66.0015.500.70816.510.22120.12380.12388.682.711.105.052.38--1.561.931.812.4121.6221.511.431.933.621.680.5829129.91-14.0913.80-31.27-0.6373.151.79
Mycodern SA1.27m-1.29m11.22m23.00--3.22--8.86-0.1046-0.10460.10230.25740.23571.143.91243,640.40-23.98-21.47-28.69-24.6357.6130.33-101.78-55.100.6937-72.040.1128--281.52-4.57-829.85---8.02--
Provexis plc801.96k-586.25k11.31m2.00--15.31--14.11-0.0003-0.00030.00040.00031.192.238.60400,980.00-87.52-47.44-61.46-33.7235.3969.87-73.34-80.901.18--0.00--105.6720.01-52.18------
Ekiz Kimya Sanayi ve Ticaret AS7.01m1.72m12.10m5.007.052.007.041.738.288.2833.8129.101.45--34.12--35.4611.2640.3016.572.591.8224.488.800.4334--0.000.00-1.5739.55-136.26------
SEKO SA46.76m2.34m12.78m431.005.450.74943.430.27321.831.8336.5313.321.8712.9110.49541,069.109.344.5811.976.4118.1816.415.012.931.27132.600.128345.2013.447.28234.9310.93-4.118.67
Onesano SA2.16m-1.27m14.14m54.00--5.86--6.54-0.0999-0.09990.17050.19020.57011.296.50211,943.40-33.39-28.15-40.54--41.8850.87-58.57-29.922.85--0.0338--0.709328.40-61.92--101.90--
Oylum Sinai Yatirimlar AS16.29m1.62m14.34m189.008.831.006.560.880.85550.85558.587.521.049.666.233,077,191.0010.4120.7513.5129.3830.9321.159.9721.152.39--0.1605--18.1772.9253.56309.2166.32--
Mlinotest dd49.80m779.20k14.45m733.0018.540.48374.570.29020.26960.269617.2310.340.91394.435.44--1.341.492.022.2528.2628.671.471.640.55184.180.333794.723.250.0774-20.20--24.57--
Data as of Nov 06 2024. Currency figures normalised to Provexis PLC's reporting currency: UK Pound GBX

Institutional shareholders

12.13%Per cent of shares held by top holders
HolderShares% Held
Hargreaves Lansdown Asset Management Ltd.as of 01 Oct 2024134.35m5.94%
HSBC Global Asset Management (UK) Ltd.as of 01 Oct 202437.81m1.67%
IG Markets Ltd.as of 01 Oct 202418.64m0.82%
Cantor Fitzgerald Europeas of 01 Oct 202417.50m0.77%
Evelyn Partners Investment Management LLPas of 01 Oct 202415.92m0.70%
Jarvis Investment Management Ltd.as of 01 Oct 202413.19m0.58%
Quilter Cheviot Ltd.as of 01 Oct 202412.66m0.56%
abrdn Investment Management Ltd.as of 01 Oct 202410.79m0.48%
Morgan Stanley Securities Ltd. (Market-Maker)as of 01 Oct 20248.50m0.38%
KW Investment Management Ltd.as of 01 Oct 20245.20m0.23%
More ▼
Data from 30 Jun 2024 - 31 Oct 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.